about
The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol.Male gynecomastiaGynecomastia and drugs: a critical evaluation of the literatureDrug-induced gynecomastia: an evidence-based reviewIn-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.Drug-induced gynecomastia.Hirsutism and the effectiveness of spironolactone in its management.Progesterone, prolactin, and gynaecomastia in men with liver disease.Polycystic ovary syndrome: chemical pharmacotherapy.Erectile impotence: a clinical challengeGynecomastia and antihypertensive therapy.The efficacy and safety of cold-induced lipolysis in the treatment of pseudogynecomastia.Gynecomastia and hypertension.Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?The risks and benefits of aldosterone antagonists.Diuretics in pediatrics : current knowledge and future prospects.Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.Testosterone in men with advanced liver disease: abnormalities and implications.Drug-induced sexual dysfunction.Endocrine effects of spironolactone in man.Pharmacosexology: the effects of drugs on sexual function a review.Sex hormone suppression and sexual impotence in hypoxic pulmonary fibrosis.Spironolactone-induced gynecomastia.Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men.Management of senescent gynecomastia in the Veterans Health Administration.Cardiovascular/Pulmonary Medications and Male Reproduction.Male breast uptake in rubidium-82 PET due to spironolactone-induced gynecomastia.Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys.Spironolactone-Induced Unilateral Gynecomastia.Drug-induced gynecomastia
P2860
Q24542420-2DE2C40F-3D03-47C9-9664-8AFB8839F24FQ24658187-88FC1072-3CFB-4161-A1B0-31E27D834A9DQ28081307-66D60B3F-B824-4BF6-AD9A-ACD2615E2EBAQ28272451-11E20D89-89FD-4EFC-9B53-E4280637B715Q34200813-2CF14F66-9C86-41F5-8CF7-28FBD28D82F7Q34312712-8F6B6A4E-5020-438F-AE2C-F25913B69EF2Q34338540-807738A6-06F6-4CC0-B620-964151A43E39Q34495111-E845BD1F-B642-4078-91A3-1912EB8A0534Q35639510-383816E8-37B1-44DF-8626-F4C321E5C916Q35805839-3938162E-80C3-49EB-9593-3DAFA02B8662Q35862007-00DF2C46-EF46-42C0-82D9-7DA8206F6986Q35964118-0778D354-35DE-46F0-8983-F1D1354406F2Q36110420-3EEE01F3-A9FC-478B-8AC6-A05BF988C6CDQ36124918-5CC5AE9A-314B-4EAD-838A-7D0672500805Q36203149-9EC32B38-9561-4F14-9DC9-1FA4B6719DF4Q36561076-3B1C3353-9F82-452B-9467-4E9ACAAD9A0AQ38182029-B8B0275E-9999-43BB-9475-1BF84AE97CC8Q38236451-311C8BEC-747F-4D4F-8F5D-CA156A59788BQ39536351-90C2EEA6-BB05-4D9C-8BC7-D1475F6A847CQ39868635-1F3F94BE-1EC9-43DC-83C7-FC220343EB30Q40087979-1E71BF0A-3FFC-49C5-BDB1-74F55041D785Q41120696-0F0D0CE8-C7AE-49F6-BC02-0670CA967BCAQ42952553-FF60347E-2A08-44B1-A559-255A857B2440Q44175058-2009D101-72CE-437D-A19E-567203A76F4AQ45330736-22A9C7BF-8B30-427D-9D0E-A4FF0D598548Q46236880-20EBC60F-2533-430F-BC79-26E8FD67D395Q53033708-2BF2AF1A-9200-4140-8081-7592A52BB709Q53671758-7BD42158-3A21-4EDB-803B-3F3D8A4C66A2Q55215645-D6D73933-78BD-412A-A042-E610DB7A5021Q57258716-D408F0E9-64BE-46FF-BF74-E4AF58EA03F3
P2860
description
1977 nî lūn-bûn
@nan
1977 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1977 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
name
Pathophysiology of spironolactone-induced gynecomastia.
@ast
Pathophysiology of spironolactone-induced gynecomastia.
@en
Pathophysiology of spironolactone-induced gynecomastia.
@nl
type
label
Pathophysiology of spironolactone-induced gynecomastia.
@ast
Pathophysiology of spironolactone-induced gynecomastia.
@en
Pathophysiology of spironolactone-induced gynecomastia.
@nl
prefLabel
Pathophysiology of spironolactone-induced gynecomastia.
@ast
Pathophysiology of spironolactone-induced gynecomastia.
@en
Pathophysiology of spironolactone-induced gynecomastia.
@nl
P2093
P1476
Pathophysiology of spironolactone-induced gynecomastia.
@en
P2093
P304
P356
10.7326/0003-4819-87-4-398
P407
P577
1977-10-01T00:00:00Z